Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
Roberto MinaAngelo BelottiMaria Teresa PetrucciRenato ZambelloAndrea CapraGiacomo Di LulloSonia RonconiNorbert PescostaMariella GrassoFederico MonacoClaudia CelliniMarco GobbiStelvio BallantiPaolo de FabritiisMaria Letizia Mosca-SiezMonia MarchettiAnna Marina LiberatiMassimo OffidaniNicola GiulianiRoberto RiaPellegrino MustoAlessandra RomanoPieter SonneveldMario BoccadoroAlessandra LaroccaPublished in: Blood cancer journal (2020)
Keyphrases
- multiple myeloma
- phase ii study
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- open label
- low dose
- acute myeloid leukemia
- prognostic factors
- peritoneal dialysis
- acute lymphoblastic leukemia
- stem cells
- locally advanced
- squamous cell carcinoma
- mesenchymal stem cells
- cell therapy
- free survival
- smoking cessation